Breaking Finance News

Barclays Capital announced Seattle Genetics (NDAQ:SGEN), raising its target price to $70.00 today

Just yesterday Seattle Genetics (NDAQ:SGEN) traded -0.42% lower at $63.53. SGEN’s 50-day average is $55.99 and its two hundred day average is $57.69. The last stock price close is up 10.49% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same period. Trade Volume was down over the average, with 359,406 shares of SGEN changing hands under the typical 1,029,560

Stating a potential upside of 0.10%, Barclays Capital bumped up the target of Seattle Genetics (NDAQ:SGEN) to $70.00

See Chart Below

Seattle Genetics (NDAQ:SGEN)

With a total market value of $0, Seattle Genetics has with a one year low of $45.31 and a one year high of $75.36 .

More About Seattle Genetics (NDAQ:SGEN)

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.